A nationwide study of the epidemiology of relapsing polychondritis
Authors Horvath A, Pall N, Molnar K, Kovats T, Surjan G, Vicsek T, Pollner P
Received 25 August 2015
Accepted for publication 4 December 2015
Published 23 June 2016 Volume 2016:8 Pages 211—230
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Christian Fynbo Christiansen
Peer reviewer comments 3
Editor who approved publication: Professor Henrik Toft Sørensen
Anna Horváth,1 Nóra Páll,2 Katalin Molnár,1 Tamás Kováts,3 György Surján,3 Tamás Vicsek,4,5 Péter Pollner2,4
13rd Department of Internal Medicine, Semmelweis University, 2Regional Science Center, Faculty of Science, Eötvös Loránd University, 3National Healthcare Service Center, 4MTA-ELTE Statistical and Biological Physics Research Group, 5Department of Biological Physics, Eötvös Loránd University Budapest, Hungary
Objective: Relapsing polychondritis (RP) is a rare autoimmune inflammatory disease that attacks mainly cartilaginous structures or causes serious damage in proteoglycan-rich structures (the eyes, heart, blood vessels, inner ear). This study shows results regarding the epidemiology, progression, and associations of this highly variable disease by collecting all cases from a 124-million-person-year Central European nationwide cohort.
Methods: We used the Hungarian Health Care Database to identify all persons with possible RP infection. We followed patients who had International Classification of Diseases 10th edition code M94.1 at least once in their inpatient or outpatient records between January 1, 2002 and December 31, 2013 in Hungary. We classified these patients into disease severity groups by their drug consumption patterns between January 1, 2010 and December 31, 2013. We analyzed the regional distribution of RP incidences as well. Overall maps of comorbidity are presented with network layouts.
Results: We identified 256 patients with RP among cumulatively 11.5 million registered inhabitants. We classified these patients into four severity classes as "extremely mild" (n=144), "mild" (n=22), "moderate" (n=41), and "severe" (n=4). Two additional groups were defined for patients without available drug data as "suspected only" (n=23) and "confirmed but unknown treatment" (n=22). The age and sex distributions of patients were similar to worldwide statistics. Indeed, the overall survival was good (95% confidence interval for 5 years was 83.6%–92.9% and for 10 years was 75.0%–88.3% which corresponds to the overall survival of the general population in Hungary), and the associations with other autoimmune disorders were high (56%) in Hungary. Almost any disease can occur with RP; however, the symptoms of chromosomal abnormalities are only incidental. Spondylosis can be a sign of the activation of RP, while Sjögren syndrome is the most frequent autoimmune association. Regional distribution of incidences suggests arsenic drinking water and sunlight exposure as possible triggering factors.
Conclusion: The good survival rate of RP in Hungary is probably associated with the early diagnosis of the disease.
Keywords: cohort of Hungary, incidence rate, severity prevalence, autoimmune comorbidity, environmental factors, network representation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]